FDA approves Reyataz
BY Advocate.com Editors
June 24 2003 12:00 AM ET
The Food and Drug Administration on Friday approved Reyataz (atazanavir), a once-daily HIV protease inhibitor developed by Bristol-Myers Squibb. The drug is the first protease inhibitor designed to be taken just once per day, significantly reducing the pill burden of HIV-positive people who often are required to take several pills several times a day. Reyataz is dosed as two 200-milligram pills taken with food. Reyataz also can be taken at the same time as other anti-HIV medications. Studies also have shown that Reyataz does not significantly boost blood-based lipid levels, a problem linked with other protease inhibitors. However, up to 24% of patients taking Reyataz can experience jaundice, resulting in a yellowing of the eyes or the skin. Studies have shown that the side effect does not appear to cause liver damage and that the jaundice dissipates when the drug is stopped. Bristol-Myers Squibb officials say the drug will be available in July. Reyataz's price has not yet been announced by the company.
- The Top 175 Essential Films of All Time for LGBT Viewers
- Rep. Steve King Wants Congress to Denounce Supreme Court's Marriage Equality Ruling
- Christian Woman Records Herself Losing It Over Marriage Equality, Gets Remixed
- South Dakota AG: Clerks Can Refuse Same-Sex Marriage Licenses
- WATCH: Rick Santorum Thinks 'People Aren't Getting Married'
- Meet the First Trans Pastor Officially Ordained by the Evangelical Lutheran Church